Physician profile
Thomas Patrick Bailey
NPI 1952325094
$9,498.24
in general payments reported to CMS, 2019-2025
48 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $1,060 · 2021: $2,022 · 2022: $1,313 · 2023: $1,586 · 2024: $1,524 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,809.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,458.11 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $801.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $743.61 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $659.81 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amarin Pharma, INC. | $634.34 | 2019-2022 | |
| Lilly USA, LLC | $605.14 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $486.82 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $431.00 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $414.48 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $376.42 | 2019-2024 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $315.56 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $271.31 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $225.51 | 2020-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.23 | 2020-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.31 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.